SBI Okasan Asset Management Co.Ltd. Purchases Shares of 30,200 Vera Therapeutics, Inc. $VERA

SBI Okasan Asset Management Co.Ltd. purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 30,200 shares of the company’s stock, valued at approximately $1,578,000.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Vera Therapeutics during the 2nd quarter valued at about $51,000. Tower Research Capital LLC TRC grew its stake in Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares during the last quarter. AlphaQuest LLC boosted its stake in shares of Vera Therapeutics by 414.2% in the third quarter. AlphaQuest LLC now owns 5,214 shares of the company’s stock worth $152,000 after buying an additional 4,200 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Vera Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock worth $157,000 after acquiring an additional 639 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

VERA has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Evercore set a $91.00 target price on Vera Therapeutics in a report on Friday, May 15th. Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price on the stock in a report on Wednesday, March 11th. Finally, HC Wainwright raised their target price on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Vera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $79.00.

Vera Therapeutics Stock Up 4.6%

Vera Therapeutics stock opened at $35.86 on Friday. The firm has a market cap of $2.57 billion, a price-to-earnings ratio of -6.47 and a beta of 0.96. The business’s 50-day moving average price is $38.58 and its 200 day moving average price is $41.16. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a 52 week low of $18.76 and a 52 week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the prior year, the firm posted ($0.81) earnings per share. As a group, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -6.17 earnings per share for the current year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 22,951 shares of the stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the transaction, the chief executive officer owned 235,244 shares in the company, valued at approximately $10,362,498.20. This represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.